Prescription Dermatology
Delgocitinib Cream/Ointment
Topical pan-JAK inhibitor for eczema and chronic hand eczema
시술 시간
외용1일1-2회
다운타임
なし
권장 횟수
8-16주で効果判定
이 치료에 대해
Delgocitinib is a topical pan-JAK inhibitor used in Japan for atopic dermatitis and recently studied/approved in some regions for chronic hand eczema. It is useful when topical steroids are inadequate or inappropriate.
Hand eczema management still requires irritant/allergen control and barrier protection.
작용 기전
Topical pan-JAK inhibition reduces local cytokine signaling and itch/inflammation pathways in skin.
적응증
일반 적응증(상세 설명 참고)
기대 효과
DELTA 1/2 showed improved IGA-CHE treatment success and patient-reported itch/pain in moderate-to-severe chronic hand eczema.
임상 근거
Bissonnette R, et al. (2024)
Delgocitinib cream in moderate-to-severe chronic hand eczema: DELTA 1 and 2. Lancet
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
DELTA FORCE investigators (2025)
Delgocitinib cream versus oral alitretinoin in severe chronic hand eczema. Lancet
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
위험 및 부작용
Application irritation, folliculitis, acneiform eruption and infection worsening may occur. Broad/long-term use requires medical supervision.